Search results
Results from the WOW.Com Content Network
A higher number of cardiovascular events has been observed in people taking sibutramine versus control (11.4% vs. 10.0%). [16] In 2010, the FDA noted the concerns that sibutramine increases the risk of heart attacks and strokes in patients with a history of cardiovascular disease.
Phentermine is an norepinephrine and dopamine releasing agent (NDRA) and produces stimulant, rewarding, and appetite suppressant effects. [8] [9] [10] Chemically, it is a substituted amphetamine. [11] Phentermine was approved for medical use in the United States in 1959. [3] It is available as a generic medication. [3]
Originally available only by prescription, it was approved by the FDA for over-the-counter sale in February 2007. [32] In May 2010, the U.S. Food and Drug Administration (FDA) approved a revised label for Xenical to include new safety information about rare cases of severe liver injury that have been reported with the use of this medication. [33]
However, it appears to act as a prodrug in vivo to metabolites that are considerably more potent and possess different ratios of monoamine reuptake inhibition in comparison, and in accordance, sibutramine behaves contrarily as an SNRI (73% and 54% for norepinephrine and serotonin reuptake inhibition, respectively) in human volunteers with only ...
Medifoxamine (Cledial, Gerdaxyl) is an antidepressant that appears to act as an SDRI as well as a 5-HT 2 receptor antagonist. [3] Sibutramine (Reductil, Meridia, Siredia, Sibutrex) is a withdrawn anorectic that itself as a molecule in vitro is an SNDRI but preferentially an SDRI, with 18.3- and 5.8-fold preference for inhibiting the reuptake of serotonin and dopamine over norepinephrine ...
Fen-phen (popular combination of fenfluramine and phentermine) 1997 Cardiotoxicity Fenclofenac: 1984 UK Cutaneous reactions; animal carcinogenicity. [3] Fenclozic acid: 1970 UK, US Hepatotoxicity. [3] Fenfluramine: 1997 European Union, UK, US, India, South Africa, others
Phentermine and topiramate was developed by Vivus, a California pharmaceutical company. In December 2009, Vivus, Inc. submitted a new drug application (NDA) to the FDA and on 1 March 2010, Vivus, Inc. announced that the FDA accepted the NDA for review.
This is the list of Schedule IV controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required for substances to be placed in this schedule: [2]